Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06385678
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Comparison of HR011408 and NovoRapid® in Subjects With Diabetics
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06375031
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT06368167
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06346925
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical Uniersity, Hefei, Anhui, China
A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 232
- Registration Number
- NCT06344091
- Locations
- 🇨🇳
Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT06308393
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06308406
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT06254742
- Locations
- 🇨🇳
Henan Cancer Hospita, Zhengzhou, Henan, China
A Study of Remimazolam Tosilate for Sedation in the ICU
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT06222294
- Locations
- 🇨🇳
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Remimazolam Tosilate for Sedation in Non-intubated Diagnostic and Therapeutic Procedures
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06216444
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath